Tumor proportion in colon cancer: results from a semiautomatic image analysis approach

Virchows Arch. 2020 Aug;477(2):185-193. doi: 10.1007/s00428-020-02764-1. Epub 2020 Feb 19.

Abstract

The tumor stroma ratio (TSR) is a promising prognostic biomarker in colon cancer, which could provide additional risk stratification for therapy adaption. The objective of our study was the investigation of the prognostic significance of TSR at different tumor sites in a simple semiautomatic approach with the open-source program ImageJ. We investigated 206 pT3 and pT4 adenocarcinomas of no special type. According to our established thresholds, 31 tumors (15%) were classified as low tumor proportion (TP) (≤ 15% TP), 42 tumors (20%) were classified as high TP (≥ 54% TP), and 133 tumors (65%) were classified as medium TP. High and low TP were associated with an adverse overall survival in comparison to medium TP (p = 0.001 and p = 0.03). Furthermore, the TP was an independent risk factor of occurrence of distant metastasis next to T status, microsatellite status, and tumor budding. The 5-year survival rate was 49% in patients with high TP, 48% in patients with low TP, and 68% in patients with medium TP (p = 0.042, n = 160). Patients with a high TP had less often tumor budding (p = 0.012), lymphovascular invasion (p = 0.049), and less harvested lymph nodes (p = 0.042) in comparison to low TP tumors. The results provide first evidence that a high tumor proportion/low stroma proportion is also associated with an adverse prognosis and that this subgroup might be difficult to identify with other classical histopathologic characteristics that are linked to an adverse prognosis.

Keywords: Biomarker; Colon cancer; ImageJ; Tumor stroma ratio.

MeSH terms

  • Adenocarcinoma / pathology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Colonic Neoplasms / diagnosis
  • Colonic Neoplasms / pathology*
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphatic Metastasis / pathology*
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Stromal Cells / pathology*
  • Survival Rate